Tags : HER2 Positive Metastatic Breast Cancer

AstraZeneca and Daiichi Sankyo Report Result of Trastuzumab Deruxtecan in

Shots: The P-II DESTINY-Breast01 study involves assessing of trastuzumab deruxtecan in 184 patients with HER2+ unresectable/ mBC prior treated with trastuzumab emtansine across 100 sites globally The P-II DESTINY- Breast01 study results: ORR (60.9%); DCR (97.3%); mDOR (14.8mos.); mPFS (16.4 mos.); estimated OS @12mos. (86%); safety & tolerability profile is consistent with P-I study Trastuzumab […]Read More